Second malignancy in hairy cell leukaemia: no evidence of increased incidence after treatment with interferon alpha

Leuk Lymphoma. 1996 Jun;22(1-2):103-6. doi: 10.3109/10428199609051735.

Abstract

The last decade has seen a dramatic improvement in prognosis of hairy cell leukaemia (HCL) but concern has emerged with regard to the incidence of second malignancy. A recent report found an 18.8% incidence of second cancers and suggested a possible role for alpha-interferon (IFN) in their pathogenesis. We reviewed our larger series of 200 patients with HCL. We found second malignancies in 8 cases (4.0%), all but one of whom had received IFN. However, when compared to age- and sex- matched population data this represents no increase in relative risk of second cancer in patients with HCL and provides no evidence of a role for IFN in the pathogenesis of these second malignancies.

Publication types

  • Review

MeSH terms

  • Adult
  • Aged
  • Female
  • Follow-Up Studies
  • Humans
  • Immunologic Factors / adverse effects*
  • Immunologic Factors / therapeutic use
  • Incidence
  • Interferon-alpha / adverse effects*
  • Interferon-alpha / therapeutic use
  • Leukemia, Hairy Cell / therapy*
  • Male
  • Middle Aged
  • Neoplasms, Second Primary / chemically induced*
  • Neoplasms, Second Primary / epidemiology
  • Retrospective Studies
  • Risk

Substances

  • Immunologic Factors
  • Interferon-alpha